Exelixis Inc (NQ: EXEL )

21.25 USD -0.40 (-1.86%)

Streaming Delayed Price Updated: 1:32 PM EDT, Oct 28, 2020 Add to My Watchlist

Price and Volume

Volume	481,898
Open	21.46
Bid (Size)	21.24 (4)
Ask (Size)	21.26 (3)
Prev. Close	21.65
Today's Range	21.05 - 21.52
52wk Range	13.67 - 27.80
Shares Outstanding	296,866,380
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal

October 27, 2020

Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX®...

Exelixis Announces First Patient Enrolled in Phase 1 Trial Cohort Evaluating XL092 in Combination with Atezolizumab in Patients with Advanced Solid Tumors

October 26, 2020

Exelixis, Inc. (NASDAQ: EXEL) today announced enrollment of the first patient into the dose-escalation cohort of the combination arm of the phase 1 trial (NCT03845166) evaluating the safety,...

Performance

YTD	+20.32%	+20.32%
1 Month	-10.46%	-10.46%
3 Month	-12.77%	-12.77%
6 Month	-20.18%	-20.18%
1 Year	+23.25%	+23.25%

More News

Exelixis to Release Third Quarter 2020 Financial Results on Thursday, November 5, 2020

October 22, 2020

U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma

October 19, 2020

Researchers Look for New Ways to Boost Diagnostic Capabilities

October 02, 2020

Exelixis Larger Than S&P 500 Component Molson Coors Beverage

October 27, 2020

Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor

October 09, 2020

Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor

October 09, 2020

First Week of December 18th Options Trading For Exelixis (EXEL)

October 23, 2020

EXEL Makes Notable Cross Below Critical Moving Average

October 21, 2020

VLU's Underlying Holdings Imply 10% Gain Potential

October 13, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.